`BIB_333`

Si L, Wei XW, Bai X, Mao L, Guo J et al. (Peking University Cancer Hospital). CAP 03: Camrelizumab plus apatinib and temozolomide as first-line treatment in patients with advanced acral melanoma. JAMA Oncol 2023; 2025 follow-up data. Key number: 64% ORR in treatment-naive unresectable Stage III/IV acral melanoma. The most consequential 2024-2025 acral-melanoma trial globally; relevant for Asian-melanoma context, not directly transferable to the patient's superficial-spreading subtype. [Tasks: 17, 18, 19b] Tier: 2 (phase 2) Grade: B Retrieved: 2026-05-15

Evidence grade: B
Tier: 2 (phase 2)
Cited by tasks: 17, 18, 19b
Identifiers: —

Full extracted findings & patient-implication analysis: bibliography/BIB_333/findings.md (research corpus). This page is a short context summary — not individualised medical advice.